Buy or sell Annexon Biosciences stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies

Annexon Biosciences Stock
Biotechnology company developing therapeutics for neurodegenerative and autoimmune disorders
About Annexon Biosciences Stock
Annexon Biosciences is the development of therapeutic products that halt the progression of complement-mediated neurodegeneration (CMND).
Funding History
August 2011 | $1000K |
---|---|
December 2014 | $34.0M |
June 2016 | $44.0M |
December 2018 | $75.0M |
Management
Chief Scientific Officer
Ted Yednock
Co-Founder
Arnon Rosenthal
President & Chief Executive Officer
Douglas Love
Other Companies

Learn More
Learn More
Pear Therapeutics
Prescription Digital Therapeutics
8Age (years)
$270MTotal Funding
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Annexon Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase